Purchase this article with an account.
Edgard Omar Rodriguez Torres, Sr., Maria A. Martinez, Hugo Quiroz Mercado, Jose L. Guerrero Naranjo, Wu Wei Chi, Robison V. Paul Chan, Kuo His Kung, Alay S. Banker; Worldwide Experiences With Intravitreal Anti-VEGFs for ROP. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3125.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of intravitreal anti-VEGF agents in ROP.
Multicentered study of 247 eyes with ROP (stage 3 and 4) treated with intravitreal anti-VEGFs (221, bevacizumab; 16, pegaptanib; 10, ranibizumab), with laser (59 eyes) and without laser (188 eyes). Birth weight and gestational age ranged from 700 to 962 grams and 24-29 weeks, respectively.
All eyes showed regression of neovascularization and normal vascular growth. Only 4 eyes had transient vitreous hemorrhage, and 10 eyes needed vitrectomy. No systemic adverse events were observed in up to 4 years follow-up.
Intravitreal anti-VEGF drugs may be safe and effective in the treatment of ROP.
Clinical Trial: :
This PDF is available to Subscribers Only